Diabetes

Diabetes screening has improved over the last two decades, yet many patients still fall through the cracks. While clinicians often rely on traditional risk models that focus on obesity, age, family history, and sedentary lifestyle, not every patient with diabetes fits that familiar picture. As a result, many diabetes cases …

Improving hemoglobin A1C has long been considered the gold standard in diabetes care. However, many clinicians now question whether lower numbers always translate into healthier, happier patients. The growing debate over how A1C levels relate to real-world diabetes outcomes highlights an important issue in modern medicine: a patient can achieve …

Everything seems to be working perfectly until it suddenly isn’t. A patient is losing weight steadily, HbA1c levels are improving, and confidence is high during every follow-up visit. Then progress slows. The scale barely changes. Blood sugar readings stop improving. Patients start asking whether the medication has stopped working, while …

Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …

A patient starts semaglutide through a telehealth platform, receives nutrition advice from a wellness clinic, and later visits a primary care physician for worsening gastrointestinal symptoms. None of the providers can see the full treatment picture. Situations like this are becoming increasingly common as GLP-1 medications move across multiple corners …

A patient loses 30 pounds, lowers their A1C, and improves their blood pressure within months of starting a GLP-1 medication. Stories like these are hard to ignore, and they have helped fuel growing enthusiasm around drugs like Ozempic, Wegovy, and Mounjaro. Yet as prescriptions continue to expand beyond high-risk diabetes …

The rapid rise of GLP-1 receptor agonists has transformed diabetes treatment and obesity management over the past decade. However, high prices and limited insurance coverage continue to restrict access for many patients. As patents evolve and global pharmaceutical markets shift, conversations about lower-cost GLP-1 therapies are gaining momentum. Clinicians are …

What if a medication designed to lower blood sugar could also help protect the brain? That question is driving growing interest among researchers studying the connection between GLP-1 drugs and Parkinson’s disease. Scientists are now exploring whether therapies originally developed for type 2 diabetes and obesity may influence inflammation, neuronal …

Managing post-meal glucose levels plays a critical role in diabetes care, yet it is often overlooked in favor of A1C and time in range. However, what happens after meals can significantly affect long-term outcomes. Think of it like traffic flow: even if the highway looks clear overall, sudden congestion at …

What if the biggest missed opportunity in diabetes care is not a new drug, but when we start using it? Early GLP-1 therapy is gaining attention as clinicians rethink traditional treatment timelines. Instead of reserving GLP-1 receptor agonists for later stages, emerging evidence suggests starting sooner may improve outcomes and …